ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于调整2025年限制性股票激励计划首次授予激励对象名单和授予数量的公告 | 2025-07-11 | Chinese | |
| 董事会薪酬与考核委员会关于公司2025年限制性股票激励计划首次授予激励对象名单（授予日）的核查意见 | 2025-07-11 | Chinese | |
| 第六届董事会第九次会议决议公告 | 2025-07-11 | Chinese | |
| 北京市竞天公诚律师事务所上海分所关于睿智医药科技股份有限公司2025年限制性股票激励计划调整及首次授予事项之法律意见书 | 2025-07-11 | Chinese | |
| 关于向激励对象首次授予限制性股票的公告 | 2025-07-11 | Chinese | |
| 自愿性信息披露管理制度 | 2025-07-11 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 36045445 | 关于调整2025年限制性股票激励计划首次授予激励对象名单和授予数量的公告 | 2025-07-11 | Chinese | ||
| 36045439 | 董事会薪酬与考核委员会关于公司2025年限制性股票激励计划首次授予激励对象名单（授予日）的核查意见 | 2025-07-11 | Chinese | ||
| 36045431 | 第六届董事会第九次会议决议公告 | 2025-07-11 | Chinese | ||
| 36045420 | 北京市竞天公诚律师事务所上海分所关于睿智医药科技股份有限公司2025年限制性股票激励计划调整及首次授予事项之法律意见书 | 2025-07-11 | Chinese | ||
| 36045405 | 关于向激励对象首次授予限制性股票的公告 | 2025-07-11 | Chinese | ||
| 36045385 | 自愿性信息披露管理制度 | 2025-07-11 | Chinese | ||
| 36045372 | 关于董事辞职暨选举职工董事的公告 | 2025-07-08 | Chinese | ||
| 36045359 | 关于出售参股公司股权的公告 | 2025-06-11 | Chinese | ||
| 36045350 | 关于投资设立全资子公司的公告 | 2025-06-11 | Chinese | ||
| 36045340 | 第六届董事会第八次会议决议公告 | 2025-06-11 | Chinese | ||
| 36045328 | 关于持股5%以上股东减持至5%以下并触及1%暨权益变动的提示性公告 | 2025-06-09 | Chinese | ||
| 36045318 | 简式权益变动报告书 | 2025-06-09 | Chinese | ||
| 36045303 | 2024年年度股东会决议公告 | 2025-05-30 | Chinese | ||
| 36045293 | 关于公司2025年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告 | 2025-05-30 | Chinese | ||
| 36045282 | 2024年年度股东会法律意见书 | 2025-05-30 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.